fda bans tirzepatide 2026 Rules and News for Compounded FDA Drug Recalls and Warnings:

Yes, though the transition from oral to injectable requires additional consideration

In the STEP 1 trial (NEJM, 2021), semaglutide 2.4mg achieved a mean weight reduction of 14.9% over 68 weeks versus 2.4% placebo establishing a benchmark that subsequent compounds including retatrutide have sought to surpass

[1] Unlike amphetamine abuse, where drug tolerance necessitates escalating doses to achieve the same effect, tolerance to clinically relevant doses of amphetamine plateaus after the initial titration period, and "drug holidays" (i.e., temporary treatment discontinuation) are not required to prevent the development of tolerance

A Note on FAERS Data and Underreporting The FDA's Adverse Event Reporting System (FAERS) captures spontaneous reports, which represent only a fraction of actual adverse events, estimates suggest under-reporting rates between 90% and 99% for non-serious events